Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics	937	34368-04-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dobutamine dobutamine hydrochloride dobutamine HCl	A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY. Molecular weight: 301.39 Formula: C18H23NO3 CLOGP: 2.43 LIPINSKI: 0 HAC: 4 HDO: 4 TPSA: 72.72 ALOGS: -4.34 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dobutamine
dobutamine hydrochloride
dobutamine HCl

A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.

Molecular weight: 301.39
Formula: C18H23NO3
CLOGP: 2.43
LIPINSKI: 0
HAC: 4
HDO: 4
TPSA: 72.72
ALOGS: -4.34
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.50	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.13 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %
CL (Clearance)	115 mL/min/kg	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	0.110		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	1.361		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	2.046	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	14.622	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	44.780	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	66.560	%	High	1
herg	hERG pIC50	4.934	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	20.277	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	11.041	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	54.880	%	High	1
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IGF1R,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70	69
kinase-selectivity-class	ACVR2B,ACVRL1,AXL,BRAF,CAMK2B,CAMK2D,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,GRK2,INSR,JAK2,MAP2K6,MAPK12,MAPK8,PRKCD,SIK2,STK33,SYK,TEK,TGFBR1,ULK1,ULK2	26
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	2.506		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	217.270		High	1
mppb	Mouse plasma protein binding (% unbound)	60.440		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	5.117		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	69.270	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	115.080	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	81.010	%	High	1
rppb	Rat plasma protein binding (% unbound)	49.540	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	595.662	uM	High	1

Approvals:

Date	Agency	Company	Orphan
July 18, 1978	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Stress cardiomyopathy	216.75	27.25	64	5440	13291	90609652
Drug ineffective	215.25	27.25	333	5171	1383965	89238978
Cardiogenic shock	205.46	27.25	71	5433	24397	90598546
Multiple organ dysfunction syndrome	135.17	27.25	71	5433	68265	90554678
Cardiac failure	83.35	27.25	62	5442	109434	90513509
Drug ineffective for unapproved indication	67.59	27.25	45	5459	66599	90556344
Vasoplegia syndrome	66.03	27.25	18	5486	2796	90620147
Toxic epidermal necrolysis	64.82	27.25	34	5470	32494	90590449
Ventricular fibrillation	56.99	27.25	24	5480	14020	90608923
Pulmonary hypertension	56.31	27.25	34	5470	42489	90580454
Septic shock	51.70	27.25	42	5462	84118	90538825
Pulmonary arterial hypertension	51.11	27.25	27	5477	26160	90596783
Cardiac arrest	49.47	27.25	45	5459	104890	90518053
Renal impairment	49.29	27.25	45	5459	105376	90517567
Ventricular tachycardia	44.08	27.25	24	5480	24684	90598259
Right ventricular failure	43.82	27.25	22	5482	19183	90603760
Ventricular hypokinesia	42.85	27.25	15	5489	5326	90617617
Sepsis	41.80	27.25	53	5451	179761	90443182
Shock	40.67	27.25	24	5480	28754	90594189
Complications of transplanted heart	40.63	27.25	7	5497	121	90622822
Condition aggravated	38.24	27.25	100	5404	595445	90027498
Left ventricle outflow tract obstruction	37.79	27.25	8	5496	424	90622519
Stevens-Johnson syndrome	37.63	27.25	23	5481	29353	90593590
Local anaesthetic systemic toxicity	36.63	27.25	12	5492	3488	90619455
Heparin-induced thrombocytopenia	35.39	27.25	13	5491	5299	90617644
Disseminated mucormycosis	34.28	27.25	8	5496	663	90622280
Respiratory failure	34.22	27.25	39	5465	118379	90504564
Hypoxia	34.01	27.25	31	5473	72368	90550575
Renal failure	32.65	27.25	40	5464	130967	90491976
Heart transplant rejection	32.46	27.25	8	5496	836	90622107
Fatigue	32.24	27.25	15	5489	1154008	89468935
Ureaplasma infection	31.91	27.25	8	5496	897	90622046
Off label use	31.49	27.25	141	5363	1102111	89520832
Haemodynamic instability	31.43	27.25	15	5489	11724	90611219
Disseminated intravascular coagulation	30.53	27.25	18	5486	21520	90601423
Status epilepticus	30.01	27.25	17	5487	18857	90604086
Hypotension	29.97	27.25	63	5441	325334	90297609
Pulmonary oedema	29.97	27.25	27	5477	62053	90560890
Lactic acidosis	28.50	27.25	24	5480	50439	90572504
Torsade de pointes	27.78	27.25	15	5489	15167	90607776
Fungal sepsis	27.69	27.25	8	5496	1533	90621410
Ascites	27.57	27.25	23	5481	47717	90575226

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	620.51	35.93	213	13647	13243	42594232
Appendicitis	549.38	35.93	218	13642	20395	42587080
Multiple organ dysfunction syndrome	455.90	35.93	320	13540	96715	42510760
Stress	440.53	35.93	236	13624	43976	42563499
Ventricular fibrillation	414.38	35.93	200	13660	29923	42577552
Ascites	357.94	35.93	225	13635	56453	42551022
Blood phosphorus increased	338.81	35.93	134	13726	12391	42595084
Abdominal distension	314.33	35.93	227	13633	71508	42535967
Myasthenia gravis	302.77	35.93	133	13727	16004	42591471
Hyperphosphataemia	272.84	35.93	116	13744	12888	42594587
Hyponatraemia	247.10	35.93	228	13632	101234	42506241
Analgesic therapy	238.48	35.93	87	13773	6437	42601038
Sleep disorder therapy	226.49	35.93	85	13775	6809	42600666
Blood uric acid increased	221.97	35.93	106	13754	15441	42592034
Drug therapy	214.47	35.93	80	13780	6300	42601175
Hypophosphataemia	214.44	35.93	114	13746	20831	42586644
Incorrect route of product administration	212.05	35.93	119	13741	24186	42583289
Neuralgia	206.09	35.93	119	13741	25528	42581947
Bacterial infection	204.67	35.93	122	13738	27757	42579718
General physical health deterioration	200.60	35.93	246	13614	151000	42456475
Sepsis	191.77	35.93	277	13583	199057	42408418
Blood cholesterol increased	191.04	35.93	115	13745	26626	42580849
Dry mouth	183.12	35.93	130	13730	39749	42567726
Iron deficiency	175.08	35.93	81	13779	10980	42596495
Antacid therapy	157.99	35.93	59	13801	4658	42602817
Activated partial thromboplastin time prolonged	150.00	35.93	82	13778	15821	42591654
Anticoagulant therapy	149.25	35.93	56	13804	4479	42602996
Constipation	128.17	35.93	206	13654	162085	42445390
Diabetes mellitus	125.07	35.93	124	13736	59963	42547512
Swelling	124.99	35.93	119	13741	54766	42552709
Thrombosis	123.78	35.93	131	13729	68380	42539095
End stage renal disease	122.86	35.93	73	13787	16485	42590990
Intentional product misuse	118.33	35.93	122	13738	61778	42545697
Abdominal pain	115.36	35.93	215	13645	190256	42417219
Chronic obstructive pulmonary disease	112.79	35.93	120	13740	62994	42544481
Ulcer	110.42	35.93	68	13792	16373	42591102
Blood calcium increased	109.64	35.93	54	13806	8400	42599075
Sleep disorder	108.96	35.93	104	13756	47991	42559484
Drug hypersensitivity	103.93	35.93	144	13716	99245	42508230
Congenital hiatus hernia	100.13	35.93	46	13814	6128	42601347
Bronchopulmonary aspergillosis allergic	96.32	35.93	41	13819	4557	42602918
Troponin increased	94.08	35.93	65	13795	18997	42588478
Drug intolerance	92.37	35.93	122	13738	80302	42527173
Condition aggravated	91.20	35.93	236	13624	260518	42346957
Blood test abnormal	90.81	35.93	55	13805	12851	42594624
Gout	88.08	35.93	73	13787	27982	42579493
Somnolence	84.95	35.93	159	13701	140946	42466529
Hyperlipidaemia	82.56	35.93	63	13797	21453	42586022
Aortic stenosis	82.18	35.93	45	13815	8700	42598775
Drug ineffective	76.60	35.93	404	13456	629793	41977682
Total lung capacity decreased	75.32	35.93	32	13828	3538	42603937
Bacteroides infection	71.01	35.93	28	13832	2559	42604916
Pulmonary embolism	70.97	35.93	134	13726	119478	42487997
Diarrhoea	65.92	35.93	34	13826	460815	42146660
Pleuritic pain	62.61	35.93	35	13825	7042	42600433
Vomiting	62.22	35.93	221	13639	289502	42317973
Stress cardiomyopathy	62.22	35.93	26	13834	2759	42604716
Fall	60.66	35.93	4	13856	234516	42372959
Aspiration	55.00	35.93	46	13814	17840	42589635
Lung opacity	54.74	35.93	30	13830	5807	42601668
Fatigue	54.05	35.93	38	13822	435603	42171872
Dizziness	52.46	35.93	9	13851	249245	42358230
Micturition urgency	50.45	35.93	37	13823	11861	42595614
Cardiogenic shock	50.33	35.93	60	13800	35580	42571895
Decreased appetite	47.92	35.93	4	13856	193133	42414342
Platelet distribution width increased	47.88	35.93	11	13849	150	42607325
Off label use	44.97	35.93	357	13503	637978	41969497
Weight decreased	44.88	35.93	7	13853	207941	42399534
Malaise	43.89	35.93	8	13852	212148	42395327
Joint injury	43.59	35.93	37	13823	14639	42592836
Breath sounds abnormal	43.31	35.93	34	13826	12059	42595416
Febrile neutropenia	43.04	35.93	5	13855	185698	42421777
Confusional state	42.90	35.93	3	13857	167594	42439881
Toxic epidermal necrolysis	42.74	35.93	48	13812	26702	42580773
Product use in unapproved indication	39.73	35.93	141	13719	184315	42423160
Pruritus	39.29	35.93	7	13853	188764	42418711
Lower respiratory tract infection	37.55	35.93	56	13804	41150	42566325

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	771.49	32.17	219	18542	14036	110556502
Multiple organ dysfunction syndrome	642.50	32.17	369	18392	151341	110419197
Appendicitis	641.61	32.17	224	18537	28240	110542298
Ventricular fibrillation	556.85	32.17	223	18538	41090	110529448
Ascites	441.87	32.17	244	18517	92564	110477974
Blood phosphorus increased	428.14	32.17	144	18617	16196	110554342
Stress	415.67	32.17	245	18516	105103	110465435
Myasthenia gravis	374.74	32.17	140	18621	21371	110549167
Hyperphosphataemia	342.56	32.17	122	18639	16259	110554279
Analgesic therapy	314.64	32.17	94	18667	7190	110563348
Sleep disorder therapy	303.69	32.17	92	18669	7379	110563159
Abdominal distension	296.53	32.17	242	18519	174861	110395677
Drug therapy	284.47	32.17	87	18674	7204	110563334
Sepsis	283.82	32.17	312	18449	327034	110243504
Blood uric acid increased	278.79	32.17	113	18648	21416	110549122
Hypophosphataemia	253.12	32.17	120	18641	33062	110537476
Hyponatraemia	251.03	32.17	242	18519	217411	110353127
Drug ineffective	244.92	32.17	683	18078	1519857	109050681
Bacterial infection	238.17	32.17	128	18633	45908	110524630
Stress cardiomyopathy	225.58	32.17	89	18672	15717	110554821
Neuralgia	223.74	32.17	125	18636	48353	110522185
Antacid therapy	212.07	32.17	65	18696	5419	110565119
Cardiogenic shock	206.82	32.17	126	18635	57212	110513326
Iron deficiency	205.47	32.17	87	18674	18389	110552149
Activated partial thromboplastin time prolonged	202.13	32.17	91	18670	22277	110548261
Anticoagulant therapy	200.78	32.17	62	18699	5299	110565239
Incorrect route of product administration	193.98	32.17	126	18635	63935	110506603
End stage renal disease	167.85	32.17	79	18682	21394	110549144
Thrombosis	160.64	32.17	139	18622	108523	110462015
Diabetes mellitus	154.79	32.17	131	18630	99250	110471288
General physical health deterioration	147.70	32.17	261	18500	425034	110145504
Chronic obstructive pulmonary disease	136.36	32.17	127	18634	109031	110461507
Constipation	135.20	32.17	228	18533	357558	110212980
Congenital hiatus hernia	132.26	32.17	47	18714	6212	110564326
Gout	125.81	32.17	78	18683	36488	110534050
Troponin increased	124.50	32.17	72	18689	29694	110540844
Intentional product misuse	124.14	32.17	132	18629	132772	110437766
Blood calcium increased	118.72	32.17	59	18702	17981	110552557
Aortic stenosis	111.24	32.17	51	18710	13008	110557530
Condition aggravated	105.46	32.17	318	18443	734518	109836020
Bronchopulmonary aspergillosis allergic	104.84	32.17	43	18718	8383	110562155
Hyperlipidaemia	104.78	32.17	69	18692	35779	110534759
Ulcer	104.69	32.17	74	18687	43042	110527496
Pulmonary embolism	102.06	32.17	152	18609	214322	110356216
Arthralgia	96.84	32.17	10	18751	779622	109790916
Blood test abnormal	95.92	32.17	60	18701	28494	110542044
Total lung capacity decreased	90.89	32.17	37	18724	7077	110563461
Somnolence	88.55	32.17	171	18590	297278	110273260
Dry mouth	88.45	32.17	137	18624	199811	110370727
Bacteroides infection	85.50	32.17	28	18733	2891	110567647
Abdominal pain	84.06	32.17	233	18528	512756	110057782
Toxic epidermal necrolysis	82.62	32.17	72	18689	56655	110513883
Fatigue	81.89	32.17	53	18708	1215905	109354633
Off label use	74.70	32.17	471	18290	1499714	109070824
Blood cholesterol increased	73.99	32.17	121	18640	184664	110385874
Fall	69.35	32.17	10	18751	603472	109967066
Lung opacity	67.59	32.17	35	18726	11617	110558921
Aspiration	66.34	32.17	49	18712	30484	110540054
Dizziness	64.94	32.17	19	18742	698174	109872364
Ventricular tachycardia	63.98	32.17	59	18702	49950	110520588
Benign prostatic hyperplasia	62.97	32.17	39	18722	18195	110552343
Vasoplegia syndrome	61.74	32.17	26	18735	5413	110565125
Micturition urgency	60.89	32.17	39	18722	19281	110551257
Pleuritic pain	59.51	32.17	36	18725	16104	110554434
Right ventricular failure	59.44	32.17	43	18718	25911	110544627
Diarrhoea	56.82	32.17	66	18695	1139439	109431099
Sleep disorder	55.18	32.17	111	18650	198533	110372005
Platelet distribution width increased	54.94	32.17	11	18750	151	110570387
Confusional state	53.28	32.17	8	18753	468672	110101866
Weight decreased	53.18	32.17	8	18753	468049	110102489
Pain in extremity	51.66	32.17	10	18751	487108	110083430
Heparin-induced thrombocytopenia	51.42	32.17	29	18732	11395	110559143
Malaise	51.26	32.17	25	18736	671794	109898744
Infusion related reaction	49.63	32.17	4	18757	381158	110189380
Pruritus	48.53	32.17	19	18742	581541	109988997
Cardiac failure	47.58	32.17	101	18660	187525	110383013
Nasopharyngitis	46.53	32.17	6	18755	394355	110176183
Abdominal discomfort	46.45	32.17	6	18755	393852	110176686
Decreased appetite	45.98	32.17	12	18749	475834	110094704
Hypersensitivity	45.67	32.17	7	18754	403991	110166547
Respiratory symptom	44.23	32.17	29	18732	14916	110555622
Drug ineffective for unapproved indication	43.39	32.17	69	18692	102769	110467769
Breath sounds abnormal	42.64	32.17	35	18726	25369	110545169
Rash	42.55	32.17	46	18715	820918	109749620
Product use in unapproved indication	41.62	32.17	168	18593	447209	110123329
Complications of transplanted heart	38.36	32.17	10	18751	462	110570076
Drug hypersensitivity	37.92	32.17	165	18596	453925	110116613
Eosinophilic myocarditis	37.86	32.17	14	18747	2071	110568467
Insomnia	36.97	32.17	8	18753	360582	110209956
Cardiovascular disorder	35.39	32.17	30	18731	22730	110547808
Heart transplant rejection	34.61	32.17	13	18748	2008	110568530
Joint injury	34.28	32.17	38	18723	39956	110530582
Low cardiac output syndrome	33.97	32.17	11	18750	1095	110569443
Blood creatinine increased	33.81	32.17	87	18674	182802	110387736
Hepatic enzyme increased	33.14	32.17	7	18754	320885	110249653
Hypernatraemia	32.97	32.17	26	18735	17807	110552731
Shock	32.94	32.17	43	18718	53545	110516993
Weight increased	32.92	32.17	15	18746	419629	110150909
Febrile neutropenia	32.53	32.17	7	18754	316760	110253778
Left ventricle outflow tract obstruction	32.33	32.17	9	18752	534	110570004

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01CA07	CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents
FDA MoA	N0000000245	Adrenergic beta-Agonists
FDA EPC	N0000175555	beta-Adrenergic Agonist
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D002316	Cardiotonic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D013566	Sympathomimetics
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D020011	Protective Agents
MeSH PA	D058665	Adrenergic beta-1 Receptor Agonists
CHEBI has role	CHEBI:35522	β-adrenergic agonist
CHEBI has role	CHEBI:35524	sympathomimetic agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:38147	cardiotonic drug
CHEBI has role	CHEBI:63726	neuroprotective agent

Related Drugs by ATC class:

C01CA Adrenergic and dopaminergic agents 25 drugs

amezinium metilsulfate arbutamine cafedrine dimetofrine dopamine dopexamine droxidopa ephedrine epinephrine etilefrine fenoldopam gepefrine show all 25 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Cardiogenic shock	indication	89138009
Decompensated cardiac failure	indication	195111005
Stress echocardiography using dobutamine	indication	703338002
Cardiac Decompensation	indication
Cardiac Decompensation Post Cardiac Surgery	indication
Organic Cardiac Disease	indication
Ventricular premature beats	contraindication	17338001
Myocardial infarction	contraindication	22298006	DOID:5844
Hypovolemia	contraindication	28560003
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypokalemia	contraindication	43339004
Atrial fibrillation	contraindication	49436004	DOID:0060224
Aortic valve stenosis	contraindication	60573004	DOID:1712
Idiopathic hypertrophic subaortic stenosis	contraindication	360465008

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.98	acidic
pKa2	10.59	acidic
pKa3	13.49	acidic
pKa4	9.03	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	AGONIST	EC50	5.50	WOMBAT-PK	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	EC50	6.20	WOMBAT-PK	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	5.98	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.00	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.42	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.87	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	5.77	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	6.91	DRUG MATRIX
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		Ki	6.32	CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.35	DRUG MATRIX
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	5.72	CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN		Ki	5.05	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	5.01	CHEMBL
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN		Ki	5.36	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	5.26	DRUG MATRIX
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	6.14	CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	6.05	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	5.37	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		IC50	5.26	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.40	DRUG MATRIX
Catechol O-methyltransferase	Enzyme	P21964	COMT_HUMAN		Km	4.30	WOMBAT-PK
Carbonic anhydrase 3	Enzyme	P07451	CAH3_HUMAN		Ki	5.13	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	5.02	CHEMBL
Carbonic anhydrase 14	Enzyme	Q9ULX7	CAH14_HUMAN		Ki	4.92	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	5.38	CHEMBL
Carbonic anhydrase 13	Enzyme	Q8N1Q1	CAH13_HUMAN		Ki	5.02	CHEMBL
Arachidonate 15-lipoxygenase	Enzyme		LOX15_RABIT		IC50	6.22	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	6.73	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	5.80	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	6.96	CHEMBL
Carbonic anhydrase 15	Enzyme		CAH15_MOUSE		Ki	6.41	CHEMBL

External reference:

ID	Source
4019730	VUID
N0000147822	NUI
D00632	KEGG_DRUG
49745-95-1	SECONDARY_CAS_RN
203121	RXNORM
4017541	VANDF
4019730	VANDF
C0012963	UMLSCUI
CHEBI:4670	CHEBI
Y00	PDB_CHEM_ID
CHEMBL926	ChEMBL_ID
CHEMBL1200418	ChEMBL_ID
DB00841	DRUGBANK_ID
D004280	MESH_DESCRIPTOR_UI
36811	PUBCHEM_CID
535	IUPHAR_LIGAND_ID
3340	INN_ID
3S12J47372	UNII
2871	MMSL
4625	MMSL
d00215	MMSL
000614	NDDF
000615	NDDF
26523005	SNOMEDCT_US
387145002	SNOMEDCT_US
90118002	SNOMEDCT_US
3S12J47372	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9141	INJECTION, SOLUTION	12.50 mg	INTRAVENOUS	ANDA	20 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1073	INJECTION	100 mg	INTRAVENOUS	NDA	18 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1075	INJECTION	200 mg	INTRAVENOUS	NDA	18 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1077	INJECTION	400 mg	INTRAVENOUS	NDA	18 sections
Dobutamine in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0025	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	18 sections
Dobutamine in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0151	INJECTION, SOLUTION	200 mg	INTRAVENOUS	NDA	18 sections
Dobutamine in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1100	INJECTION, SOLUTION	400 mg	INTRAVENOUS	NDA	18 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2344	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2344	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
Dobutamine in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2346	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	18 sections
Dobutamine in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2347	INJECTION, SOLUTION	200 mg	INTRAVENOUS	NDA	18 sections
Dobutamine in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3724	INJECTION, SOLUTION	400 mg	INTRAVENOUS	NDA	18 sections
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	14335-171	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	14335-172	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4562	INJECTION	400 mg	INTRAVENOUS	NDA	18 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1330	INJECTION, SOLUTION	200 mg	INTRAVENOUS	NDA	12 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1337	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	12 sections
DOBUTAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1566	INJECTION	100 mg	INTRAVENOUS	NDA	11 sections
DOBUTAMINE IN DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1664	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	12 sections
DOBUTAMINE IN DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1697	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	11 sections
DOBUTAMINE IN DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1705	INJECTION, SOLUTION	200 mg	INTRAVENOUS	NDA	12 sections
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5717	INJECTION, SOLUTION	12.50 mg	INTRAVENOUS	ANDA	11 sections
Dobutamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5777	INJECTION, SOLUTION	400 mg	INTRAVENOUS	NDA	12 sections
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	70436-203	INJECTION	250 mg	INTRAVENOUS	ANDA	21 sections

Ask DrugCentral

Try a sample question

dobutamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: